Accéder au contenu
Merck
  • Successful medical treatment in a child with E. coli ESBL meningitis with acute communicating hydrocephalus and ventricular empyema: a case report.

Successful medical treatment in a child with E. coli ESBL meningitis with acute communicating hydrocephalus and ventricular empyema: a case report.

Journal of the Medical Association of Thailand = Chotmaihet thangphaet (2013-03-22)
Chanapai Chaiyakulsil, Olarn Prommalikit
RÉSUMÉ

Extended-spectrum beta-lactamase (ESBL) producing organisms cause wide spectrum of diseases including urinary tract infection, cholangitis, intra-abdominal abscess or pneumonia but rarely meningitis. The present report a successful nonsurgical, medical treatment in a child with Escherichia coli ESBL meningitis with acute symptomatic communicating hydrocephalus and ventricular empyema. Incidence of infections from ESBL producing organisms are increasingly emerging and causing wide spectrum of illnesses which prompts for both aggressive medical and surgical intervention to prevent morbidity and mortality. Antimicrobial agents must be vigilantly utilized to prevent possible development of new highly-resistant organisms.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Pénicillinase from Bacillus cereus, lyophilized powder, 1,500-3,000 units/mg protein (using benzylpenicillin)
Sigma-Aldrich
β-Lactamase, recombinant, expressed in E. coli
Sigma-Aldrich
β-Lactamase from Enterobacter cloacae, Type IV, lyophilized powder, 0.2-0.6 units/mg protein (using benzylpenicillin)
Sigma-Aldrich
Pénicillinase from Bacillus cereus, lyophilized, powder, white, ~13 U/mg
Sigma-Aldrich
β-Lactamase from Pseudomonas fluorescens, lyophilized powder, recombinant, expressed in E. coli